Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) EPS (Basic): 2009-2024

Historic EPS (Basic) for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to -$0.09.

  • Heron Therapeutics' EPS (Basic) fell 233.33% to -$0.10 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.08, marking a year-over-year increase of 50.00%. This contributed to the annual value of -$0.09 for FY2024, which is 88.75% up from last year.
  • As of FY2024, Heron Therapeutics' EPS (Basic) stood at -$0.09, which was up 88.75% from -$0.80 recorded in FY2023.
  • Heron Therapeutics' 5-year EPS (Basic) high stood at -$0.09 for FY2024, and its period low was -$2.50 during FY2020.
  • Moreover, its 3-year median value for EPS (Basic) was -$0.80 (2023), whereas its average is -$0.85.
  • Data for Heron Therapeutics' EPS (Basic) shows a peak YoY surged of 88.75% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Heron Therapeutics' EPS (Basic) stood at -$2.50 in 2020, then increased by 10.40% to -$2.24 in 2021, then climbed by 25.45% to -$1.67 in 2022, then surged by 52.10% to -$0.80 in 2023, then skyrocketed by 88.75% to -$0.09 in 2024.